Sarah Howell, Ph.D., Chief Executive Officer
Sarah, who joined Arecor in 2013, before being appointed Chief Executive Officer to the Group in 2015, has a strong background in clinical and commercial pharmaceutical product development, manufacture, supply and licensing across a range of product types and therapeutic areas. She has served in a number of leading roles in the pharmaceutical industry, most recently as Vice President for CMC (Chemistry, Manufacturing & Controls) and Technical Development for BTG where she had full responsibility for CMC development and supply across BTG’s diverse portfolio of clinical and commercial products.
Jan Jezek, Ph.D., Chief Scientific Officer
Jan is a biochemist with a strong background in physical chemistry and the principal inventor of the core protein stabilisation technologies. Currently he is responsible at Arecor for R&D activities, platform development and IP strategy. He played a critical role in the development of stabilising technologies for commercially important therapeutic proteins and vaccines that form the core of Arecor business.
David Gerring, Head of Development
David has 15 years’ experience in pharmaceutical product and analytical development, as well as significant regulatory and quality experience. He has held senior roles at Immunocore and Emmergent BioSolutions and his experience includes 5 years at UCB, whilst in a scientific and regulatory capacity. There, he focused on the development and successful licensure of Cimzia. He headed up process and analytical development at BTG, managing CMC for several recombinant products, including successful INDs and licensures.
Fiona Lawrence, Director of Project Management
Fiona is a pharmaceutical research and development professional and is currently Director of Project Management at Arecor, where she has responsibility for driving the clinical development of proprietary product portfolio products.
Laura Cicciolini, Ph.D., Director of Business Development
Laura joined Arecor in 2018 as Head of Business Development. Coming from a background in Engineering, she has gained international experience across a number of business functions in the pharmaceutical, biotechnology and engineering/technology industries. She is multi-lingual and has built and trained successful teams, developed products and services, and managed complex programmes on a global scale, enabling expansion of businesses across markets.